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CORRESPONDENCE
Letters to the Editor
A Call for Development
of Comprehensive
Therapy for Dyslipidemia
Treatment of hyperlipidemia with statins has become an integral
part of management of vascular disease today. However, numerous
gray areas exist in the treatment algorithm. The meta-analysis by
Cannon et al. (1) refers to usage of high-dose statin therapy for
low-density lipoprotein (LDL) reduction in the treatment of
cardiovascular diseases. The title of the study uses the term
“Intensive Versus Moderate Statin Therapy,” which apparently is a
new term being coined for high-dose statin therapy. None of the
trials included in the meta-analysis use this term to define the dose
of atorvastatin. In all these trials the prime focus was the level of LDL
achieved and event reduction following that. The atorvastatin dosage
has never been shown to be an independent predictor of long-term
outcome in multivariate analysis. Thus, any dose of atorvastatin or
any other statin that achieves the desired level of LDL of about 70
mg/dl would be considered as optimal statin therapy according to
the current knowledge. Whether the term “intensive” relates to a
high dose of atorvastatin or to a dose of statin that reduces LDL
to about 70 mg/dl is not clear. Hence, the new term of “intensive
statin therapy” is probably not required in today’s clinical jargon.
Whether adequate LDL reduction if achieved using a smaller
dose of statins will confer similar benefit as that with high-dose
statins is not clear due to lack of data. As the pleiotropic effect
cannot be easily measured in clinical practice, the real target for a
clinician today is LDL cholesterol. Most of the large-scale trials
also use the same target and compare the long-term outcomes with
LDL reduction or levels achieved. It would be interesting to
perform a subgroup analysis of patients receiving 10 mg of
atorvastatin and reaching an LDL target of 70 mg/dl in the trials
included in the researchers’ meta-analysis.
It is also very important to understand the same dose of a drug
may not be required in all races to achieve the desired effect. In
clinical practice in India, most of our colleagues have been able to
maintain LDL levels close to 70 mg/dl with much lower doses of
atorvastatin. As of today no important trial data is available to us
from the region, and thus we rely heavily on Western literature. In
this case, what would be an “intensive statin therapy” for an Asian
Indian remains a very difficult question to answer. Thus, a term of
“optimal lipid-lowering therapy” seems more useful and less
confusing than intensive statin therapy.
Low high-density lipoprotein (HDL) is another important
contributor to development of atherosclerotic vascular disease. In
fact, rapid regression of atheroma has only been shown with
infusion of apolipoprotein A-I milano (2). Further, results from
the MIRACL (Myocardial Ischemia Reduction with Aggressive
Cholesterol Lowering) study (3) involving 3,086 patients have
shown that HDL and not LDL cholesterol levels influence
short-term prognosis after acute coronary syndrome (ACS). It is
also documented that HDL modulation is better with lower doses
of atorvastatin than with higher doses and even better when
low-dose atorvastatin is combined with ezetimibe.
Reduction in C-reactive protein is probably the only measurable
pleiotropic effect of statins. Comparable C-reactive protein reduc-
tion has also been shown with combination of low-dose simvasta-
tin and ezetimibe to that of high-dose atorvastatin, although in a
short-term study (4). Reduction in LDL with a combination of
low-dose atorvastatin and ezetimibe has been comparable to that
with high-dose atorvastatin alone, again in a short-term study (5).
In light of these facts, it is very important that we develop a
comprehensive hyperlipidemia therapy that encompasses adequate
LDL reduction along with reduction in total cholesterol and
triglycerides and elevation of HDL at the same time, rather than
harping on high-dose statin therapy.
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Reply
We would like to thank Drs. Deshpande, Mardikar, and Deo for
their important comments regarding our study (1). The term
“intensive” statin therapy has recently been used to identify statin
regimens that lower low-density lipoprotein cholesterol (LDL-C)
by approximately 50%, as we did in the PROVE IT–TIMI-22
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(Pravastatin or Atorvastatin Evaluation and Infection Therapy)
trial: “Intensive Versus Moderate Lipid Lowering With Statins
After Acute Coronary Syndromes” (2). On the active debate
regarding whether the appropriate treatment should be based on
the dose of the statin or the achieved LDL, we agree that there
have not been trials that directly compare 2 strategies of titrating to
a specific LDL-C goal. All the trials use different, largely fixed
regimens of a specific statin dose (either with intensive vs.
moderate, or of statin therapy vs. placebo). In PROVE IT–TIMI-
22, we designed the trial very specifically to have 2 different levels
of achieved LDL-C so as to be able to compare patients who
reached an average of 100 mg/dl, as recommended in the
National Cholesterol Education Program (NCEP) III guidelines,
versus a much lower LDL-C with a more intensive regimen, with
the final median LDL-C values of 95 and 62 mg/dl, respectively.
Almost a decade ago, the NCEP Guideline committee adopted
a practical approach to lipid lowering—where members specified
target levels for LDL-C and other lipid levels. This was believed to
be a means of having physicians identify high cholesterol values in
patients and adjust treatment accordingly. The evidence directly
supporting this approach does not exist, as recently lamented (3),
but can be inferred from all the randomized trials.
For clinical care, we take a practical view. If we have a patient
with an LDL70 mg/dl on a moderate dose of a statin, we do not
feel compelled to increase the dose. However, we are currently
conducting the IMPROVE IT trial to address this question, to
ascertain whether an even lower LDL is even better. It compares
strategies using simvastatin versus simvastatin plus ezetimibe,
which are anticipated to have achieved LDL levels of 65 versus
50 mg/dl, respectively. When the trial is completed in several
years, we may have evidence to support an even lower target
level for LDL.
For additional targets of therapy, we agree, and published the
prospective analysis relating clinical event rates to levels of achieved
C-reactive protein (4). We similarly have recently found triglyc-
erides to be an important target for therapy (5). We agree that
HDL is an important target as well, and we anticipate new
approaches to address this important risk factor. All these data
support the call for comprehensive management of all components
of dyslipidemia.
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Depression and Heart Failure:
Why the Link Continues
to Elude Us
Rutledge et al.’s (1) important and comprehensive review of depres-
sion in heart failure highlights the relative neglect in investigating
the key parameters of this important association in the litera-
ture. The researchers remind us there remains as yet no in-
vestigation of the effects of a depression intervention on objective
clinical outcomes such as survival or secondary cardiac events in a
heart failure (HF) population.
However, although their useful review emphasized the biolog-
ical connections between HF and depression, some of the emerg-
ing key issues on the link between depression and heart disease
possibly emphasize more the social and perceptual impacts of
effect.
For example, we know that depression has a negative impact on
social networks, and it could be that it partially mediates its effects
on cardiovascular systems via this variable. It is now a well-
established finding that those individuals who are more socially
integrated—for example, in long-term relationships or connected
to communities or organizations—display lower risks of premature
all-cause mortality than do those who are not so well integrated
socially (2).
Piferi and Lawler (2) have recently demonstrated that social
support not only had a positive impact on blood pressure but giving
social support appears to represent a separate construct from
receiving social support and may exert a uniquely positive effect on
health. It might be that future studies on depression and HF,
particularly intervention ones, would need to take this kind of
social mediating variable into account, and be highly specific as to
whether giving or receiving social support was measured.
Another key aspect of depression, which should be part of the
future of research into depression and HF, is the specific impact of
low mood on perception. For example, Ruo et al. (3) recently
established that depression has a clinically significant effect on
self-rated health among women with coronary disease, even after
adjustment for clinical diagnoses. The magnitude of this impact of
depression on self-rated health was similar to that of major
cardiovascular events such as angina, myocardial infarction, angio-
plasty, HF, or coronary bypass surgery.
Whether depressed individuals are less compliant with treat-
ments and medical advice, and whether they are unlikely to attend
follow-up, are recalcitrant over exercise, losing weight, improving
diet, and quitting smoking remain open questions. Thus, the
precise pathway via how their depression impacts on their physical
health continues to be a mystery.
This gap in our current knowledge probably accounts for the
recent failure to demonstrate a significant impact on physical out-
comes for treating depression following myocardial infarction (4).
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